Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access

Puntos clave

• Biosimilar trastuzumab shows improved cost-utility for treating HER2-positive breast cancer, making it a viable alternative.
• The analysis indicates a budget impact that supports wider access to biosimilar treatments in Thailand.
• Evaluation utilized cost-utility analysis to assess financial and health outcomes of biosimilar trastuzumab.
• Wider access to the biosimilar could reduce financial burdens on patients, highlighting the need for policy consideration.